Novavax defended at Cantor citing prospects for COVID-19 shot outside U.S.
naphtalina/iStock via Getty Images
- Novavax (NASDAQ:NVAX) tumbled nearly 20% on Friday after the company pushed back the timeline for seeking U.S. regulatory nod for the COVID-19 shot once again.
- The clinical-stage vaccine developer now intends to file for…
